FLAG-Ida Regimen as Bridge Therapy to Allotransplantation in Refractory/Relapsed Acute Myeloid Leukemia Patients

Allotransplant is crucial for improving survival in refractory/first relapsed AML patients. An overall response was achieved in 48 patients (44% of the whole group) with FLAG-Ida chemotherapy approach. 24 of 48 responders underwent allotransplantation obtaining a median OS of 60 months.

Source: Clinical Lymphoma, Myeloma and Leukemia - June 19, 2017 Category: Hematology Authors: Mario Delia, Domenico Pastore, Paola Carluccio, Crescenza Pasciolla, Alessandra Ricco, Antonella Russo Rossi, Paola Casieri, Anna Mestice, Francesco Albano, Giorgina Specchia Tags: Original Study Source Type: research